Quarterly Returns (%)Alnylam Pharmaceuticals Inc
| Years | Q1 | Q2 | Q3 | Q4 | Annual |
|---|---|---|---|---|---|
| 2004 | 0 | 25.8 | -23.8 | 29.7 | 0 |
| 2005 | -1.9 | -0.4 | 54.8 | 18.2 | 78.9 |
| 2006 | 31.7 | -14.3 | -4.4 | 51.7 | 60.2 |
| 2007 | -15.9 | -13.3 | 107.3 | -11.5 | 35.9 |
| 2008 | -16.1 | 9.6 | 8.3 | -14.6 | -15 |
| 2009 | -23 | 17 | 1.8 | -22.3 | -28.8 |
| 2010 | -3.4 | -11.8 | -18.3 | -19.6 | -44 |
| 2011 | -3 | -2 | -29.9 | 24.1 | -17.3 |
| 2012 | 35.8 | 5 | 54.9 | -3.2 | 123.9 |
| 2013 | 33.5 | 31.8 | 94 | 0.5 | 252.3 |
| 2014 | 4.4 | -5.9 | 23.6 | 24.2 | 50.9 |
| 2015 | 7.7 | 14.8 | -33 | 17.2 | -3 |
| 2016 | -33.3 | -11.6 | 22.2 | -44.8 | -60.2 |
| 2017 | 36.9 | 55.6 | 47.3 | 3.9 | 239.3 |
| 2018 | -6.3 | -2.7 | -10.8 | -17.5 | -42.6 |
| 2019 | 28.2 | -21.4 | 10 | 48.1 | 59.1 |
| 2020 | -5 | 4 | 8 | -10.7 | 12 |
| 2021 | 8.6 | 20.1 | 9 | -5.6 | 34.2 |
| 2022 | -6.4 | -10.7 | 37.2 | 18.7 | 36.3 |
| 2023 | -15.7 | -5.2 | -6.8 | 7 | -19.5 |
| 2024 | -22 | 61.1 | 20.9 | -15.9 | 22.9 |
| 2025 | -0.4 | 0 | 0 | -0.4 |